Figure 3 shows that I2 supplementation is accompanied by a significant increase in the expression of T-BET and IFNγ, and by the repression of TGFβ in early-stage tumors (I2). In advanced-stage tumors, I2 generates a decrease in the Th2 polarization marker GATA3 (Cht+I2). These data indicate that the presence of iodine at any stage induces an oncogenic polarization through Th1. The overexpression of T-BET and IFNγ was also detected at the protein level in tumor tissues of early-state patients supplemented with I2 compared to placebo (Figure 4). The gene discussed is SLC5A7; the disease is neoplasm.